{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:53:40Z","timestamp":1790704420164,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"DOI":"10.1093\/jac\/dku400","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T06:04:47Z","timestamp":1413612287000},"page":"534-542","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women*"],"prefix":"10.1093","volume":"70","author":[{"given":"Angela","family":"Colbers","sequence":"first","affiliation":[{"name":"Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias I Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Ivanovic","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases \u2018L. Spallanzani\u2019, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabamba","family":"Kabeya","sequence":"additional","affiliation":[{"name":"Saint-Pierre University Hospital, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Chelsea & Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gingelmaier","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen, Frauenklinik Innenstadt, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Taylor","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Weizs\u00e4cker","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Geburtsmedizin, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Tariq","family":"Sadiq","sequence":"additional","affiliation":[{"name":"Institution for Infection and Immunity, St George's, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marchina","family":"Van der Ende","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[{"name":"University of Padua, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burger","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PANNA Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. A. M.","family":"van der Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Warris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Faetkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schwarze-Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,17]]},"reference":[{"key":"key\n\t\t\t\t20180328164715_DKU400C1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ajog.2007.03.081","article-title":"Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999\u20132001","volume":"197","author":"Harris","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"key\n\t\t\t\t20180328164715_DKU400C2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/QAD.0000000000000212","article-title":"Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000\u20132011","volume":"28","author":"Townsend","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328164715_DKU400C3","article-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","author":"DHHS"},{"key":"key\n\t\t\t\t20180328164715_DKU400C4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavir\/ritonavir 800\/100 mg once-daily in treatment-naive and -experienced patients","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180328164715_DKU400C5","article-title":"Prezista; FDA Label Information","author":"FDA","year":"2014"},{"key":"key\n\t\t\t\t20180328164715_DKU400C6","article-title":"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States","author":"DHHS"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20180328164715_DKU400C7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-1293.2012.01030.x","article-title":"British HIV Association guidelines for the management of HIV infection in pregnant women 2012","volume":"13","author":"Taylor","year":"2012","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328164715_DKU400C8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180328164715_DKU400C9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180328164715_DKU400C10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hiv.12047","article-title":"Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir\/ritonavir 600\/100 mg administered twice daily","volume":"15","author":"Zorrilla","year":"2014","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328164715_DKU400C11","article-title":"Pharmacokinetics of darunavir once or twice daily during pregnancy and postpartum","author":"Capparelli"},{"key":"key\n\t\t\t\t20180328164715_DKU400C12","article-title":"Safety, efficacy and pharmacokinetic of darunavir\/ritonavir containing regimen in pregnant HIV-infected women","author":"Courbon"},{"key":"key\n\t\t\t\t20180328164715_DKU400C13","article-title":"Darunavir\/ritonavir once daily total and unbound plasmatic concentrations in HIV-infected pregnant women","author":"Curran"},{"key":"key\n\t\t\t\t20180328164715_DKU400C14","article-title":"Total and unbound pharmacokinetics of once-daily darunavir\/ritonavir in HIV-1-infected pregnant women","author":"Crauwels"},{"key":"key\n\t\t\t\t20180328164715_DKU400C15","article-title":"Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 Through 31 July 2013","author":"APRegistry"},{"key":"key\n\t\t\t\t20180328164715_DKU400C16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/QAD.0b013e32802ef2f6","article-title":"Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis","volume":"21","author":"Kourtis","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328164715_DKU400C17","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1471-0528.2010.02689.x","article-title":"Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe","volume":"117","author":"Townsend","year":"2010","journal-title":"BJOG"},{"key":"key\n\t\t\t\t20180328164715_DKU400C18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/infdis\/jis728","article-title":"Combination antiretroviral use and preterm birth","volume":"207","author":"Watts","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328164715_DKU400C19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00007691-200306000-00023","article-title":"Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography","volume":"25","author":"Droste","year":"2003","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180328164715_DKU400C20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ftd.0000211817.58052.b8","article-title":"Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring","volume":"28","author":"Holland","year":"2006","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180328164715_DKU400C21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/FTD.0b013e31820fa528","article-title":"The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program","volume":"33","author":"Burger","year":"2011","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180328164715_DKU400C22","first-page":"53","article-title":"Conceptualization, measurement, and use of gestational age. I. Clinical and public health practice","volume":"16","author":"Alexander","year":"1996","journal-title":"J Perinatol"},{"key":"key\n\t\t\t\t20180328164715_DKU400C23","article-title":"Pharmacokinetic\/pharmacodynamic analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients","author":"Sekar"},{"key":"key\n\t\t\t\t20180328164715_DKU400C24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/QAI.0b013e31820fd093","article-title":"Atazanavir pharmacokinetics with and without tenofovir during pregnancy","volume":"56","author":"Mirochnick","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328164715_DKU400C25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAI.0b013e318289b4d2","article-title":"Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy","volume":"63","author":"Kreitchmann","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328164715_DKU400C26","article-title":"Clinical Report Synopsis: Phase I, Open-Label, Randomized, 3-Way Crossover Trial to Assess the Pharmacokinetics of Darunavir (DRV) Given Once-Daily With Different Doses of Ritonavir in Healthy Subjects","author":"Tibotec","year":"2009"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/70\/2\/534\/13759634\/dku400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T03:24:24Z","timestamp":1650425064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/2\/534\/2911273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,17]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,10,17]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku400","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,17]]}}}